ARS Pharmaceuticals, Inc. SPRY Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: ARS Pharmaceuticals, Inc.’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s pre-tax income?
- ARS Pharmaceuticals, Inc. (SPRY) reported pre-tax income of -$42.84M in Q4 2025.
- How has ARS Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
- ARS Pharmaceuticals, Inc.'s pre-tax income decreased by 2168.3% year-over-year, from $2.07M to -$42.84M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s pre-tax income?
- Over 2 years (2023 to 2025), ARS Pharmaceuticals, Inc.'s pre-tax income has grown at a 77.5% compound annual growth rate (CAGR), from -$54.37M to -$171.38M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.